INDIGO: An Analysis of the Baseline Molecular Characterization of Patients From SNO-2023 INDIGO: An Analysis of the Baseline Molecular Characterization of Patients From SNO-2023

Tim Cloughesy reviews the key baseline molecular characteristics of patients treated in the recent phase 3 INDIGO trial.Medscape Medical Affairs

Source: Medscape Today Headlines - December 14, 2023 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news